

16<sup>th</sup> January, 2026

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

Dear Sir / Madam,

Pursuant to Regulation 30(6) of the SEBI Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.

Kindly take this on record.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**

Encl: a/a

## Q3 and 9M FY2026 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **29<sup>th</sup> January 2026** from **9:30 AM to 10:15 AM (IST)** to discuss its **Q3 and 9M FY2026 Results**.

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 29 <sup>th</sup> January, 2026	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 11:00 PM (Eastern Time – New York)	Toll free number 18667462133
	UK – 04:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – <a href="#">Click Here</a>	

### About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE:PPLPHARMA | BSE:543635), offers a portfolio of differentiated products and services through its 17\* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

\* Includes one facility via PPL's minority investment in Yapan Bio

### For Queries:

Gagan Borana

Investor Relations & Enterprise Risk Management

[gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)